title: Occult invasive cervical cancer found after inadvertent simple hysterectomy: is the ideal management: systematic parametrectomy with or without radiotherapy or radiotherapy only?
abstract: BACKGROUND
  After the diagnosis of occult cervical cancer during simple hysterectomy, is the best treatment option for the patient surgery with or without radiotherapy or radiation therapy only? Our study aims to answer this question.
  
  
  METHODS
  We retrospectively analyzed 29 patients with occult cervical cancer found after inadvertent simple hysterectomy and who were referred to our cancer center between 2000 and 2010. All of the patients were discussed by the tumor board. Thirteen patients underwent surgery (radical parametrectomy and pelvic lymphadenectomy) using the minimally invasive approach (surgical group), and 16 patients underwent pelvic lymphadenectomy and radiation therapy or concurrent chemoradiation (radiation group).
  
  
  RESULTS
  Age, BMI, and the tumor diameter were not statistically different between the surgical and radiation group: 44 and 49 (± 11) years (p = .23), 24.6 (± 6.2) and 26.7 (± 5) (p = 0.33), and 22 (± 13) and 31 (± 11) mm (p = .09), respectively. The 5-year overall and disease-free survivals for the surgical and radiation groups were: 100 and 77 % (p = .04), and 86 and 37 % (p = .02), respectively. These results were statistically significant.
  
  
  CONCLUSIONS
  In the case of occult cervical cancer found after simple hysterectomy, radical parametrectomy with pelvic lymphadenectomy using minimally invasive surgery seems to be more efficient than radiation therapy or concurrent chemoradiation, with acceptable minimal morbidity being observed.
authors.affiliation: Department of Gynecologic Oncology, Centre Oscar Lambret Cancer Center, Lille, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Narducci
authors.forename: Benjamin
authors.initials: B
authors.lastname: Merlot
authors.forename: Lucie
authors.initials: L
authors.lastname: Bresson
authors.forename: Ninad
authors.initials: N
authors.lastname: Katdare
authors.forename: Florence
authors.initials: F
authors.lastname: Le Tinier
authors.forename: Abel
authors.initials: A
authors.lastname: Cordoba
authors.forename: Charles
authors.initials: C
authors.lastname: Fournier
authors.forename: Eric
authors.initials: E
authors.lastname: Leblanc
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000209:etiology / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000209:etiology / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D009367:Neoplasm Staging; D011183:Postoperative Complications; D011379:Prognosis; D018714:Radiotherapy, Adjuvant / Q000401:mortality*; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D055815:Young Adult